nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulfadiazine—CYP3A4—bone cancer	0.878	1	CbGaD
Sulfadiazine—Diuresis—Cisplatin—bone cancer	0.00495	0.0464	CcSEcCtD
Sulfadiazine—Skin necrosis—Cisplatin—bone cancer	0.00439	0.0411	CcSEcCtD
Sulfadiazine—Necrolysis epidermal—Methotrexate—bone cancer	0.00371	0.0347	CcSEcCtD
Sulfadiazine—Reaction gastrointestinal—Methotrexate—bone cancer	0.00252	0.0236	CcSEcCtD
Sulfadiazine—Anuria—Methotrexate—bone cancer	0.00241	0.0226	CcSEcCtD
Sulfadiazine—Skin necrosis—Methotrexate—bone cancer	0.00241	0.0226	CcSEcCtD
Sulfadiazine—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.0023	0.172	CbGpPWpGaD
Sulfadiazine—Anuria—Epirubicin—bone cancer	0.00225	0.0211	CcSEcCtD
Sulfadiazine—Skin necrosis—Epirubicin—bone cancer	0.00225	0.0211	CcSEcCtD
Sulfadiazine—Skin necrosis—Doxorubicin—bone cancer	0.00209	0.0195	CcSEcCtD
Sulfadiazine—Anuria—Doxorubicin—bone cancer	0.00209	0.0195	CcSEcCtD
Sulfadiazine—Body temperature increased—Carboplatin—bone cancer	0.00147	0.0138	CcSEcCtD
Sulfadiazine—Skin exfoliation—Cisplatin—bone cancer	0.00146	0.0137	CcSEcCtD
Sulfadiazine—Eruption—Methotrexate—bone cancer	0.00137	0.0128	CcSEcCtD
Sulfadiazine—Eruption—Epirubicin—bone cancer	0.00128	0.012	CcSEcCtD
Sulfadiazine—Polyuria—Cisplatin—bone cancer	0.00127	0.0119	CcSEcCtD
Sulfadiazine—Haemolytic anaemia—Cisplatin—bone cancer	0.00123	0.0116	CcSEcCtD
Sulfadiazine—Burning sensation—Methotrexate—bone cancer	0.00121	0.0114	CcSEcCtD
Sulfadiazine—Eruption—Doxorubicin—bone cancer	0.00118	0.0111	CcSEcCtD
Sulfadiazine—Anaphylactoid reaction—Cisplatin—bone cancer	0.00115	0.0108	CcSEcCtD
Sulfadiazine—Burning sensation—Epirubicin—bone cancer	0.00113	0.0106	CcSEcCtD
Sulfadiazine—Neuritis—Epirubicin—bone cancer	0.00106	0.00989	CcSEcCtD
Sulfadiazine—Burning sensation—Doxorubicin—bone cancer	0.00105	0.00983	CcSEcCtD
Sulfadiazine—Neuritis—Doxorubicin—bone cancer	0.000976	0.00915	CcSEcCtD
Sulfadiazine—Pancreatitis—Cisplatin—bone cancer	0.000943	0.00884	CcSEcCtD
Sulfadiazine—Blood disorder—Epirubicin—bone cancer	0.000943	0.00884	CcSEcCtD
Sulfadiazine—Skin discolouration—Methotrexate—bone cancer	0.000932	0.00873	CcSEcCtD
Sulfadiazine—Oliguria—Methotrexate—bone cancer	0.000913	0.00856	CcSEcCtD
Sulfadiazine—Blood disorder—Doxorubicin—bone cancer	0.000873	0.00818	CcSEcCtD
Sulfadiazine—Skin discolouration—Epirubicin—bone cancer	0.000872	0.00817	CcSEcCtD
Sulfadiazine—Oliguria—Epirubicin—bone cancer	0.000855	0.00801	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Cisplatin—bone cancer	0.000841	0.00788	CcSEcCtD
Sulfadiazine—Stomatitis—Cisplatin—bone cancer	0.000836	0.00784	CcSEcCtD
Sulfadiazine—Skin discolouration—Doxorubicin—bone cancer	0.000807	0.00756	CcSEcCtD
Sulfadiazine—Skin exfoliation—Methotrexate—bone cancer	0.000804	0.00753	CcSEcCtD
Sulfadiazine—Oliguria—Doxorubicin—bone cancer	0.000791	0.00741	CcSEcCtD
Sulfadiazine—Aplastic anaemia—Methotrexate—bone cancer	0.00079	0.00741	CcSEcCtD
Sulfadiazine—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000755	0.0564	CbGpPWpGaD
Sulfadiazine—Skin exfoliation—Epirubicin—bone cancer	0.000752	0.00705	CcSEcCtD
Sulfadiazine—Aplastic anaemia—Epirubicin—bone cancer	0.00074	0.00693	CcSEcCtD
Sulfadiazine—Sepsis—Methotrexate—bone cancer	0.00073	0.00685	CcSEcCtD
Sulfadiazine—Tinnitus—Cisplatin—bone cancer	0.000718	0.00673	CcSEcCtD
Sulfadiazine—Polyuria—Methotrexate—bone cancer	0.000696	0.00652	CcSEcCtD
Sulfadiazine—Skin exfoliation—Doxorubicin—bone cancer	0.000696	0.00652	CcSEcCtD
Sulfadiazine—Aplastic anaemia—Doxorubicin—bone cancer	0.000684	0.00641	CcSEcCtD
Sulfadiazine—Sepsis—Epirubicin—bone cancer	0.000684	0.00641	CcSEcCtD
Sulfadiazine—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000652	0.0488	CbGpPWpGaD
Sulfadiazine—Dermatitis exfoliative—Methotrexate—bone cancer	0.000647	0.00607	CcSEcCtD
Sulfadiazine—Vascular purpura—Epirubicin—bone cancer	0.000639	0.00599	CcSEcCtD
Sulfadiazine—Sepsis—Doxorubicin—bone cancer	0.000632	0.00593	CcSEcCtD
Sulfadiazine—Anaphylactoid reaction—Methotrexate—bone cancer	0.000631	0.00592	CcSEcCtD
Sulfadiazine—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000624	0.0466	CbGpPWpGaD
Sulfadiazine—Dermatitis exfoliative—Epirubicin—bone cancer	0.000606	0.00568	CcSEcCtD
Sulfadiazine—Leukopenia—Cisplatin—bone cancer	0.0006	0.00563	CcSEcCtD
Sulfadiazine—Purpura—Epirubicin—bone cancer	0.000593	0.00556	CcSEcCtD
Sulfadiazine—Vascular purpura—Doxorubicin—bone cancer	0.000591	0.00554	CcSEcCtD
Sulfadiazine—Anaphylactoid reaction—Epirubicin—bone cancer	0.000591	0.00554	CcSEcCtD
Sulfadiazine—Hypoglycaemia—Epirubicin—bone cancer	0.000586	0.00549	CcSEcCtD
Sulfadiazine—Convulsion—Cisplatin—bone cancer	0.000581	0.00544	CcSEcCtD
Sulfadiazine—Ataxia—Methotrexate—bone cancer	0.000574	0.00538	CcSEcCtD
Sulfadiazine—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000561	0.00525	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00055	0.00516	CcSEcCtD
Sulfadiazine—Purpura—Doxorubicin—bone cancer	0.000549	0.00514	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Cisplatin—bone cancer	0.000547	0.00513	CcSEcCtD
Sulfadiazine—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000547	0.00512	CcSEcCtD
Sulfadiazine—Hypoglycaemia—Doxorubicin—bone cancer	0.000542	0.00508	CcSEcCtD
Sulfadiazine—Ataxia—Epirubicin—bone cancer	0.000538	0.00504	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Cisplatin—bone cancer	0.000536	0.00502	CcSEcCtD
Sulfadiazine—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000531	0.0397	CbGpPWpGaD
Sulfadiazine—Sulfasalazine—PTGS2—bone cancer	0.000522	0.257	CrCbGaD
Sulfadiazine—Anorexia—Cisplatin—bone cancer	0.000522	0.00489	CcSEcCtD
Sulfadiazine—Pancreatitis—Methotrexate—bone cancer	0.000518	0.00485	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000515	0.00483	CcSEcCtD
Sulfadiazine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000508	0.0379	CbGpPWpGaD
Sulfadiazine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000499	0.00467	CcSEcCtD
Sulfadiazine—Ataxia—Doxorubicin—bone cancer	0.000497	0.00466	CcSEcCtD
Sulfadiazine—Pancreatitis—Epirubicin—bone cancer	0.000485	0.00454	CcSEcCtD
Sulfadiazine—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000476	0.00446	CcSEcCtD
Sulfadiazine—Decreased appetite—Cisplatin—bone cancer	0.000476	0.00446	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000472	0.00443	CcSEcCtD
Sulfadiazine—Depression—Methotrexate—bone cancer	0.000469	0.0044	CcSEcCtD
Sulfadiazine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000467	0.00437	CcSEcCtD
Sulfadiazine—Stomatitis—Methotrexate—bone cancer	0.000459	0.0043	CcSEcCtD
Sulfadiazine—Pancreatitis—Doxorubicin—bone cancer	0.000448	0.0042	CcSEcCtD
Sulfadiazine—Sulfamethoxazole—CYP3A4—bone cancer	0.000442	0.217	CrCbGaD
Sulfadiazine—Agranulocytosis—Methotrexate—bone cancer	0.000439	0.00412	CcSEcCtD
Sulfadiazine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000437	0.00409	CcSEcCtD
Sulfadiazine—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000435	0.0325	CbGpPWpGaD
Sulfadiazine—Body temperature increased—Cisplatin—bone cancer	0.000433	0.00405	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Epirubicin—bone cancer	0.000432	0.00405	CcSEcCtD
Sulfadiazine—Stomatitis—Epirubicin—bone cancer	0.000429	0.00403	CcSEcCtD
Sulfadiazine—Hepatitis—Methotrexate—bone cancer	0.000423	0.00396	CcSEcCtD
Sulfadiazine—Agranulocytosis—Epirubicin—bone cancer	0.000411	0.00385	CcSEcCtD
Sulfadiazine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000408	0.0305	CbGpPWpGaD
Sulfadiazine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000404	0.00379	CcSEcCtD
Sulfadiazine—Hypersensitivity—Cisplatin—bone cancer	0.000403	0.00378	CcSEcCtD
Sulfadiazine—Erythema multiforme—Methotrexate—bone cancer	0.0004	0.00375	CcSEcCtD
Sulfadiazine—Neuropathy peripheral—Doxorubicin—bone cancer	0.0004	0.00375	CcSEcCtD
Sulfadiazine—Stomatitis—Doxorubicin—bone cancer	0.000397	0.00372	CcSEcCtD
Sulfadiazine—Hepatitis—Epirubicin—bone cancer	0.000396	0.00371	CcSEcCtD
Sulfadiazine—Tinnitus—Methotrexate—bone cancer	0.000394	0.00369	CcSEcCtD
Sulfadiazine—Sulfanilamide—CYP3A4—bone cancer	0.000387	0.19	CrCbGaD
Sulfadiazine—Agranulocytosis—Doxorubicin—bone cancer	0.00038	0.00357	CcSEcCtD
Sulfadiazine—Chills—Methotrexate—bone cancer	0.000379	0.00355	CcSEcCtD
Sulfadiazine—Diarrhoea—Cisplatin—bone cancer	0.000374	0.00351	CcSEcCtD
Sulfadiazine—Erythema multiforme—Epirubicin—bone cancer	0.000374	0.00351	CcSEcCtD
Sulfadiazine—Tinnitus—Epirubicin—bone cancer	0.000369	0.00346	CcSEcCtD
Sulfadiazine—Hepatitis—Doxorubicin—bone cancer	0.000366	0.00343	CcSEcCtD
Sulfadiazine—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.000364	0.0272	CbGpPWpGaD
Sulfadiazine—Chills—Epirubicin—bone cancer	0.000355	0.00333	CcSEcCtD
Sulfadiazine—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.00035	0.0262	CbGpPWpGaD
Sulfadiazine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00035	0.0262	CbGpPWpGaD
Sulfadiazine—Vomiting—Cisplatin—bone cancer	0.000348	0.00326	CcSEcCtD
Sulfadiazine—Erythema multiforme—Doxorubicin—bone cancer	0.000346	0.00324	CcSEcCtD
Sulfadiazine—Dapsone—CYP3A4—bone cancer	0.000345	0.17	CrCbGaD
Sulfadiazine—Rash—Cisplatin—bone cancer	0.000345	0.00323	CcSEcCtD
Sulfadiazine—Dermatitis—Cisplatin—bone cancer	0.000345	0.00323	CcSEcCtD
Sulfadiazine—Tinnitus—Doxorubicin—bone cancer	0.000341	0.0032	CcSEcCtD
Sulfadiazine—Dapsone—PTGS2—bone cancer	0.000338	0.166	CrCbGaD
Sulfadiazine—Vertigo—Methotrexate—bone cancer	0.000331	0.0031	CcSEcCtD
Sulfadiazine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000329	0.0246	CbGpPWpGaD
Sulfadiazine—Leukopenia—Methotrexate—bone cancer	0.000329	0.00309	CcSEcCtD
Sulfadiazine—Chills—Doxorubicin—bone cancer	0.000328	0.00308	CcSEcCtD
Sulfadiazine—Nausea—Cisplatin—bone cancer	0.000325	0.00305	CcSEcCtD
Sulfadiazine—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000325	0.0243	CbGpPWpGaD
Sulfadiazine—Convulsion—Methotrexate—bone cancer	0.000319	0.00299	CcSEcCtD
Sulfadiazine—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000315	0.0235	CbGpPWpGaD
Sulfadiazine—Arthralgia—Methotrexate—bone cancer	0.000313	0.00294	CcSEcCtD
Sulfadiazine—Vertigo—Epirubicin—bone cancer	0.000309	0.0029	CcSEcCtD
Sulfadiazine—Leukopenia—Epirubicin—bone cancer	0.000308	0.00289	CcSEcCtD
Sulfadiazine—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000303	0.0226	CbGpPWpGaD
Sulfadiazine—Anaphylactic shock—Methotrexate—bone cancer	0.0003	0.00281	CcSEcCtD
Sulfadiazine—Convulsion—Epirubicin—bone cancer	0.000298	0.0028	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Methotrexate—bone cancer	0.000294	0.00276	CcSEcCtD
Sulfadiazine—Arthralgia—Epirubicin—bone cancer	0.000293	0.00275	CcSEcCtD
Sulfadiazine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000287	0.0214	CbGpPWpGaD
Sulfadiazine—Vertigo—Doxorubicin—bone cancer	0.000286	0.00268	CcSEcCtD
Sulfadiazine—Anorexia—Methotrexate—bone cancer	0.000286	0.00268	CcSEcCtD
Sulfadiazine—Leukopenia—Doxorubicin—bone cancer	0.000285	0.00267	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Epirubicin—bone cancer	0.000281	0.00263	CcSEcCtD
Sulfadiazine—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000281	0.021	CbGpPWpGaD
Sulfadiazine—Convulsion—Doxorubicin—bone cancer	0.000276	0.00259	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Epirubicin—bone cancer	0.000275	0.00258	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000274	0.00256	CcSEcCtD
Sulfadiazine—Insomnia—Methotrexate—bone cancer	0.000272	0.00255	CcSEcCtD
Sulfadiazine—Arthralgia—Doxorubicin—bone cancer	0.000271	0.00254	CcSEcCtD
Sulfadiazine—Anorexia—Epirubicin—bone cancer	0.000268	0.00251	CcSEcCtD
Sulfadiazine—Decreased appetite—Methotrexate—bone cancer	0.000261	0.00245	CcSEcCtD
Sulfadiazine—Anaphylactic shock—Doxorubicin—bone cancer	0.00026	0.00244	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000259	0.00243	CcSEcCtD
Sulfadiazine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000256	0.0191	CbGpPWpGaD
Sulfadiazine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000256	0.0024	CcSEcCtD
Sulfadiazine—Thrombocytopenia—Doxorubicin—bone cancer	0.000255	0.00239	CcSEcCtD
Sulfadiazine—Insomnia—Epirubicin—bone cancer	0.000254	0.00238	CcSEcCtD
Sulfadiazine—Anorexia—Doxorubicin—bone cancer	0.000248	0.00232	CcSEcCtD
Sulfadiazine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000246	0.0184	CbGpPWpGaD
Sulfadiazine—Gastrointestinal pain—Methotrexate—bone cancer	0.000246	0.0023	CcSEcCtD
Sulfadiazine—Decreased appetite—Epirubicin—bone cancer	0.000244	0.00229	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000243	0.00227	CcSEcCtD
Sulfadiazine—Urticaria—Methotrexate—bone cancer	0.000239	0.00224	CcSEcCtD
Sulfadiazine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000238	0.0178	CbGpPWpGaD
Sulfadiazine—Body temperature increased—Methotrexate—bone cancer	0.000237	0.00222	CcSEcCtD
Sulfadiazine—Abdominal pain—Methotrexate—bone cancer	0.000237	0.00222	CcSEcCtD
Sulfadiazine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000237	0.00222	CcSEcCtD
Sulfadiazine—Insomnia—Doxorubicin—bone cancer	0.000235	0.0022	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Epirubicin—bone cancer	0.00023	0.00215	CcSEcCtD
Sulfadiazine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000228	0.0171	CbGpPWpGaD
Sulfadiazine—Decreased appetite—Doxorubicin—bone cancer	0.000226	0.00212	CcSEcCtD
Sulfadiazine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000224	0.0021	CcSEcCtD
Sulfadiazine—Urticaria—Epirubicin—bone cancer	0.000223	0.00209	CcSEcCtD
Sulfadiazine—Abdominal pain—Epirubicin—bone cancer	0.000222	0.00208	CcSEcCtD
Sulfadiazine—Body temperature increased—Epirubicin—bone cancer	0.000222	0.00208	CcSEcCtD
Sulfadiazine—Hypersensitivity—Methotrexate—bone cancer	0.000221	0.00207	CcSEcCtD
Sulfadiazine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000213	0.00199	CcSEcCtD
Sulfadiazine—Pruritus—Methotrexate—bone cancer	0.000212	0.00199	CcSEcCtD
Sulfadiazine—Hypersensitivity—Epirubicin—bone cancer	0.000207	0.00194	CcSEcCtD
Sulfadiazine—Urticaria—Doxorubicin—bone cancer	0.000207	0.00194	CcSEcCtD
Sulfadiazine—Body temperature increased—Doxorubicin—bone cancer	0.000206	0.00193	CcSEcCtD
Sulfadiazine—Abdominal pain—Doxorubicin—bone cancer	0.000206	0.00193	CcSEcCtD
Sulfadiazine—Diarrhoea—Methotrexate—bone cancer	0.000205	0.00193	CcSEcCtD
Sulfadiazine—Pruritus—Epirubicin—bone cancer	0.000199	0.00186	CcSEcCtD
Sulfadiazine—Diarrhoea—Epirubicin—bone cancer	0.000192	0.0018	CcSEcCtD
Sulfadiazine—Hypersensitivity—Doxorubicin—bone cancer	0.000192	0.0018	CcSEcCtD
Sulfadiazine—Vomiting—Methotrexate—bone cancer	0.000191	0.00179	CcSEcCtD
Sulfadiazine—Rash—Methotrexate—bone cancer	0.000189	0.00177	CcSEcCtD
Sulfadiazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000189	0.0141	CbGpPWpGaD
Sulfadiazine—Dermatitis—Methotrexate—bone cancer	0.000189	0.00177	CcSEcCtD
Sulfadiazine—Headache—Methotrexate—bone cancer	0.000188	0.00176	CcSEcCtD
Sulfadiazine—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000187	0.014	CbGpPWpGaD
Sulfadiazine—Pruritus—Doxorubicin—bone cancer	0.000184	0.00172	CcSEcCtD
Sulfadiazine—Vomiting—Epirubicin—bone cancer	0.000179	0.00167	CcSEcCtD
Sulfadiazine—Nausea—Methotrexate—bone cancer	0.000178	0.00167	CcSEcCtD
Sulfadiazine—Diarrhoea—Doxorubicin—bone cancer	0.000178	0.00167	CcSEcCtD
Sulfadiazine—Rash—Epirubicin—bone cancer	0.000177	0.00166	CcSEcCtD
Sulfadiazine—Dermatitis—Epirubicin—bone cancer	0.000177	0.00166	CcSEcCtD
Sulfadiazine—Headache—Epirubicin—bone cancer	0.000176	0.00165	CcSEcCtD
Sulfadiazine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000176	0.0131	CbGpPWpGaD
Sulfadiazine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000168	0.0125	CbGpPWpGaD
Sulfadiazine—Nausea—Epirubicin—bone cancer	0.000167	0.00156	CcSEcCtD
Sulfadiazine—Vomiting—Doxorubicin—bone cancer	0.000165	0.00155	CcSEcCtD
Sulfadiazine—Rash—Doxorubicin—bone cancer	0.000164	0.00154	CcSEcCtD
Sulfadiazine—Dermatitis—Doxorubicin—bone cancer	0.000164	0.00154	CcSEcCtD
Sulfadiazine—Headache—Doxorubicin—bone cancer	0.000163	0.00153	CcSEcCtD
Sulfadiazine—Nausea—Doxorubicin—bone cancer	0.000154	0.00145	CcSEcCtD
Sulfadiazine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000151	0.0113	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000151	0.0113	CbGpPWpGaD
Sulfadiazine—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000149	0.0112	CbGpPWpGaD
Sulfadiazine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000131	0.00977	CbGpPWpGaD
Sulfadiazine—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000129	0.00964	CbGpPWpGaD
Sulfadiazine—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000123	0.00916	CbGpPWpGaD
Sulfadiazine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000106	0.00795	CbGpPWpGaD
Sulfadiazine—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000106	0.00792	CbGpPWpGaD
Sulfadiazine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000105	0.00785	CbGpPWpGaD
Sulfadiazine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.62e-05	0.00645	CbGpPWpGaD
Sulfadiazine—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	8.6e-05	0.00642	CbGpPWpGaD
Sulfadiazine—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	6.7e-05	0.00501	CbGpPWpGaD
Sulfadiazine—CYP2E1—Biological oxidations—CYP3A4—bone cancer	6.51e-05	0.00487	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	6.42e-05	0.0048	CbGpPWpGaD
Sulfadiazine—CYP2C8—Biological oxidations—CYP3A4—bone cancer	5.63e-05	0.00421	CbGpPWpGaD
Sulfadiazine—CYP2E1—Biological oxidations—GSTP1—bone cancer	5.57e-05	0.00416	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	5.55e-05	0.00415	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	5.49e-05	0.00411	CbGpPWpGaD
Sulfadiazine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	5.45e-05	0.00408	CbGpPWpGaD
Sulfadiazine—CYP2C8—Biological oxidations—GSTP1—bone cancer	4.81e-05	0.0036	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	4.75e-05	0.00355	CbGpPWpGaD
Sulfadiazine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	4.58e-05	0.00342	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	4.52e-05	0.00338	CbGpPWpGaD
Sulfadiazine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.99e-05	0.00298	CbGpPWpGaD
Sulfadiazine—CYP2C9—Biological oxidations—GSTP1—bone cancer	3.92e-05	0.00293	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—NDUFA12—bone cancer	3.9e-05	0.00292	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	3.86e-05	0.00289	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—NDUFA12—bone cancer	3.37e-05	0.00252	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—NT5C3A—bone cancer	3.23e-05	0.00242	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—NT5C3A—bone cancer	2.8e-05	0.00209	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—NDUFA12—bone cancer	2.75e-05	0.00205	CbGpPWpGaD
Sulfadiazine—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.58e-05	0.00193	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.55e-05	0.0019	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—NT5C3A—bone cancer	2.28e-05	0.0017	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—NDUFA12—bone cancer	1.81e-05	0.00135	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—NT5C3A—bone cancer	1.5e-05	0.00112	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—ENO2—bone cancer	1.42e-05	0.00106	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—DHFR—bone cancer	1.31e-05	0.000982	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—GNA11—bone cancer	1.23e-05	0.000918	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—ENO2—bone cancer	1.22e-05	0.000915	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—DHFR—bone cancer	1.14e-05	0.000849	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—CYP3A4—bone cancer	1.11e-05	0.000832	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—GNA11—bone cancer	1.06e-05	0.000794	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—ENO2—bone cancer	9.97e-06	0.000745	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—CYP3A4—bone cancer	9.63e-06	0.000719	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.58e-06	0.000716	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—GSTP1—bone cancer	9.53e-06	0.000712	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—DHFR—bone cancer	9.25e-06	0.000691	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—GNA11—bone cancer	8.64e-06	0.000646	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—GSTP1—bone cancer	8.23e-06	0.000615	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—CYP3A4—bone cancer	7.84e-06	0.000586	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.8e-06	0.000583	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—GSTP1—bone cancer	6.7e-06	0.000501	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—ENO2—bone cancer	6.57e-06	0.000491	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—DHFR—bone cancer	6.1e-06	0.000456	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—GNA11—bone cancer	5.7e-06	0.000426	CbGpPWpGaD
Sulfadiazine—CYP2E1—Metabolism—PTGS2—bone cancer	4.93e-06	0.000369	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—GSTP1—bone cancer	4.42e-06	0.00033	CbGpPWpGaD
Sulfadiazine—CYP2C8—Metabolism—PTGS2—bone cancer	4.27e-06	0.000319	CbGpPWpGaD
Sulfadiazine—CYP2C9—Metabolism—PTGS2—bone cancer	3.47e-06	0.000259	CbGpPWpGaD
Sulfadiazine—CYP3A4—Metabolism—PTGS2—bone cancer	2.29e-06	0.000171	CbGpPWpGaD
